Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $12.50

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $12.50.

Several analysts recently commented on the company. UBS Group lowered their target price on ALX Oncology from $25.00 to $4.00 and set a "buy" rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ALX Oncology in a report on Monday, August 12th. HC Wainwright reiterated a "buy" rating and issued a $25.00 target price on shares of ALX Oncology in a research report on Tuesday, August 13th. Lifesci Capital lowered shares of ALX Oncology from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 31st. Finally, Stifel Nicolaus reiterated a "hold" rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th.

ALX Oncology Stock Performance

ALXO stock traded up $0.02 during mid-day trading on Friday, reaching $1.45. The company had a trading volume of 752,799 shares, compared to its average volume of 685,068. The stock's 50-day simple moving average is $1.85 and its two-hundred day simple moving average is $6.45. The stock has a market capitalization of $76.37 million, a P/E ratio of -0.40 and a beta of 1.03. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.06. ALX Oncology has a one year low of $1.34 and a one year high of $17.83.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.01. Research analysts anticipate that ALX Oncology will post -3.04 EPS for the current year.

Institutional Trading of ALX Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALXO. CANADA LIFE ASSURANCE Co acquired a new stake in shares of ALX Oncology during the first quarter worth $27,000. EntryPoint Capital LLC acquired a new stake in ALX Oncology during the 1st quarter worth about $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock valued at $39,000 after buying an additional 5,200 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of ALX Oncology in the second quarter worth about $63,000. Finally, AQR Capital Management LLC increased its position in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock worth $109,000 after acquiring an additional 6,080 shares in the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.